Literature DB >> 28664561

A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome.

M McCarron1, P McCallion2, E Reilly3, P Dunne3, R Carroll1, N Mulryan3.   

Abstract

GOAL: To examine dementia characteristics, age at onset and associated co-morbidities in persons with Down syndrome.
METHOD: A total of 77 people with Down syndrome aged 35 years and older were followed up from 1996 to 2015. The diagnosis of dementia was established using the modified ICD 10 Criteria and a combination of objective and informant-based tests. Cognitive tests included the Test for Severe Impairment and the Down Syndrome Mental Status Examination; adaptive behaviour was measured using the Daily Living Skills Questionnaire, and data from the Dementia Questionnaire for People with Intellectual Disabilities have been available since 2005.
RESULTS: Over the 20-year period, 97.4% (75 of 77) persons developed dementia with a mean age of dementia diagnosis of 55 years (SD = 7.1, median = 56 years). Clinical dementia was associated with cognitive and function decline and seizure activity. Risk for dementia increased from 23% in those aged 50 years to 80% in those aged 65 years and above. There were no differences by level of ID.
CONCLUSION: The previously reported high risk levels for dementia among people with Down syndrome were confirmed in this data as was the relationship with late onset epilepsy. The value of the instruments utilised in tracking decline and helping to confirm diagnosis is further highlighted.
© 2017 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.

Entities:  

Keywords:  Down syndrome; dementia; longitudinal

Mesh:

Year:  2017        PMID: 28664561     DOI: 10.1111/jir.12390

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  51 in total

1.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

2.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

3.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Authors:  Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

Review 4.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

5.  Evaluation of the National Task Group-Early Detection Screen for Dementia: Sensitivity to 'mild cognitive impairment' in adults with Down syndrome.

Authors:  Wayne Silverman; Sharon J Krinsky-McHale; Florence Lai; H Diana Rosas; Christy Hom; Eric Doran; Margaret Pulsifer; Ira Lott; Nicole Schupf
Journal:  J Appl Res Intellect Disabil       Date:  2020-12-13

6.  Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.

Authors:  James A Hendrix; David C Airey; Angela Britton; Anna D Burke; George T Capone; Ronelyn Chavez; Jacqueline Chen; Brian Chicoine; Alberto C S Costa; Jeffrey L Dage; Eric Doran; Anna Esbensen; Casey L Evans; Kelley M Faber; Tatiana M Foroud; Sarah Hart; Kelsey Haugen; Elizabeth Head; Suzanne Hendrix; Hampus Hillerstrom; Priya S Kishnani; Kavita Krell; Duvia Lara Ledesma; Florence Lai; Ira Lott; Cesar Ochoa-Lubinoff; Jennifer Mason; Jessie Nicodemus-Johnson; Nicholas Kyle Proctor; Margaret B Pulsifer; Carolyn Revta; H Diana Rosas; Tracie C Rosser; Stephanie Santoro; Kim Schafer; Thomas Scheidemantel; Frederick Schmitt; Brian G Skotko; Melissa R Stasko; Amy Talboy; Amy Torres; Kristi Wilmes; Jason Woodward; Jennifer A Zimmer; Howard H Feldman; William Mobley
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

7.  Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome.

Authors:  Karly A Cody; Brianna Piro-Gambetti; Matthew D Zammit; Bradley T Christian; Benjamin L Handen; William E Klunk; Shahid Zaman; Sterling C Johnson; David T Plante; Sigan L Hartley
Journal:  Neurobiol Aging       Date:  2020-04-29       Impact factor: 4.673

8.  Opportunities, barriers, and recommendations in down syndrome research.

Authors:  James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi
Journal:  Transl Sci Rare Dis       Date:  2021-04-15

9.  The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population.

Authors:  Sarah E Pape; Tamara Al Janabi; Nicholas J Ashton; Abdul Hye; Rory Sheehan; Paul Gallagher; Bernice Knight; Anne-Marije Prins; Ken Courtenay; Vesna Jordanova; Bini Thomas; Nagarajan Perumal; Craig Forbes; Angela Hassiotis; Andre Strydom
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.

Authors:  Alberto Lleó; Henrik Zetterberg; Jordi Pegueroles; Thomas K Karikari; María Carmona-Iragui; Nicholas J Ashton; Victor Montal; Isabel Barroeta; Juan Lantero-Rodríguez; Laura Videla; Miren Altuna; Bessy Benejam; Susana Fernandez; Silvia Valldeneu; Diana Garzón; Alexandre Bejanin; Maria Florencia Iulita; Valle Camacho; Santiago Medrano-Martorell; Olivia Belbin; Jordi Clarimon; Sylvain Lehmann; Daniel Alcolea; Rafael Blesa; Kaj Blennow; Juan Fortea
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.